Biqiang Zheng1,2, Jian Wang3,2, Weiluo Cai1,2, Iweng Lao3,2, Yingqiang Shi1,2, Xiaoying Luo4, Wangjun Yan1,2. 1. Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 4. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.
Abstract
BACKGROUND: Little is known about how the tumor immune microenvironment (TIME) is modulated in recurrent soft tissue sarcomas (STS). METHODS: We evaluated CD8+ T cells, CD20+ B cells, Foxp3+ regulatory T cells (Tregs), and programmed cell death ligand 1 (PD-L1) in 72 paired pre-recurrent (1st resected) versus post-recurrent (2nd resected) STS by immunohistochemistry. Correlations with time to recurrence and prognosis were determined. RESULTS: We found that CD8, PD-L1, CD20, and Foxp3-positive cell counts changed in post-recurrent STS. PD-L1-positive tumor cell and lymphocyte counts increased in post-recurrent STS, whereas CD8+ T cell counts decreased. Changes in CD8+ T cell, CD20+ B cell, and PD-L1+ lymphocyte counts were associated with the time interval between surgeries. At admission, fewer CD8+ T cells were detected in patients with relapse than in newly diagnosed patients. Furthermore, post-recurrent STS with fewer CD8+ T cells compared with pre-recurrent STS were more likely to exhibit re-recurrence. The change in CD8+ T cells was positively associated with overall survival. In multivariate analyses, a decrease in CD8+ T cell counts in post-recurrent STS was an independent unfavorable prognostic factor. CONCLUSIONS: The TIME differs between pre-recurrent STS and post-recurrent STS. The variation in CD8+ T cells and PD-L1 positivity may have essential roles during tumor relapse and provides a basis for determining therapeutic strategies.
BACKGROUND: Little is known about how the tumor immune microenvironment (TIME) is modulated in recurrent soft tissue sarcomas (STS). METHODS: We evaluated CD8+ T cells, CD20+ B cells, Foxp3+ regulatory T cells (Tregs), and programmed cell death ligand 1 (PD-L1) in 72 paired pre-recurrent (1st resected) versus post-recurrent (2nd resected) STS by immunohistochemistry. Correlations with time to recurrence and prognosis were determined. RESULTS: We found that CD8, PD-L1, CD20, and Foxp3-positive cell counts changed in post-recurrent STS. PD-L1-positive tumor cell and lymphocyte counts increased in post-recurrent STS, whereas CD8+ T cell counts decreased. Changes in CD8+ T cell, CD20+ B cell, and PD-L1+ lymphocyte counts were associated with the time interval between surgeries. At admission, fewer CD8+ T cells were detected in patients with relapse than in newly diagnosed patients. Furthermore, post-recurrent STS with fewer CD8+ T cells compared with pre-recurrent STS were more likely to exhibit re-recurrence. The change in CD8+ T cells was positively associated with overall survival. In multivariate analyses, a decrease in CD8+ T cell counts in post-recurrent STS was an independent unfavorable prognostic factor. CONCLUSIONS: The TIME differs between pre-recurrent STS and post-recurrent STS. The variation in CD8+ T cells and PD-L1 positivity may have essential roles during tumor relapse and provides a basis for determining therapeutic strategies.
Authors: M V Dieci; C Criscitiello; A Goubar; G Viale; P Conte; V Guarneri; G Ficarra; M C Mathieu; S Delaloge; G Curigliano; F Andre Journal: Ann Oncol Date: 2014-01-08 Impact factor: 32.976
Authors: Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund Journal: PLoS One Date: 2011-01-27 Impact factor: 3.240
Authors: Omid Hamid; Henrik Schmidt; Aviram Nissan; Laura Ridolfi; Steinar Aamdal; Johan Hansson; Michele Guida; David M Hyams; Henry Gómez; Lars Bastholt; Scott D Chasalow; David Berman Journal: J Transl Med Date: 2011-11-28 Impact factor: 5.531
Authors: C Rothermundt; J S Whelan; P Dileo; S J Strauss; J Coleman; T W Briggs; S R Haile; B M Seddon Journal: Br J Cancer Date: 2014-04-15 Impact factor: 7.640
Authors: Sean J Judge; Morgan A Darrow; Steve W Thorpe; Alicia A Gingrich; Edmond F O'Donnell; Alyssa R Bellini; Ian R Sturgill; Logan V Vick; Cordelia Dunai; Kevin M Stoffel; Yue Lyu; Shuai Chen; May Cho; Robert B Rebhun; Arta M Monjazeb; William J Murphy; Robert J Canter Journal: J Immunother Cancer Date: 2020-11 Impact factor: 13.751